Drug
IRDye800 clinical trials
- studies test it
- 11
- open now
- 9
- in phase 3
- 0
- first study started
- 2016
Keep track of what changes. Save the IRDye800 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 11
Vanderbilt-Ingram Cancer Center (3) · Stanford University (3) · Eben Rosenthal (2) · Andrei Iagaru (1) · George Poultsides (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses IRDye800 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT07741643Written as Panitumumab-IRDye800
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical ProceduresRecruitingEarly Phase 1Eben RosenthalNCT07493447Written as Panitumumab-IRDye800
- Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During SurgeryRecruitingPhase 1/2Stanford UniversityNCT03582124Written as Panitumumab-IRDye800
- Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical ProceduresRecruitingPhase 1/2Stanford UniversityNCT04085887Written as Panitumumab-IRDye800
- Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT06819228Written as Panitumumab IRDye 800
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing SurgeryRecruitingPhase 1/2Stanford UniversityNCT03510208Written as Panitumumab-IRDye800
- Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing SurgeryRecruitingPhase 1/2George PoultsidesNCT03384238Written as Panitumumab-IRDye800
- Phase II Panitumumab-IRDye800 in Head & Neck CancerRecruitingPhase 2University of Alabama at BirminghamNCT04511078Written as Panitumumab-IRDye800
- Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT05945875Written as Panitumumab-IRDye800
- Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck CancerCompletedPhase 1Andrei IagaruNCT03733210Written as Panitumumab-IRDye800
- Panitumumab IRDye800 Optical Imaging StudyCompletedPhase 1Eben RosenthalNCT02415881Written as Panitumumab IRDye 800